期刊
SURGICAL INFECTIONS
卷 19, 期 8, 页码 757-768出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/sur.2018.233
关键词
active immunity; adaptive immunity; passive immunity; Pseudomonas aeruginosa; T(H)17; vaccine
资金
- Cystic Fibrosis Foundation [PRIEBE17G0]
- Richard A. and Susan F. Smith President's Innovation Award
- Technology and Innovation Development Office (TIDO) at Boston Children's Hospital
- Translational Research for Infection Prevention in Pediatric Anesthesia and CriticalCare (TRIPPACC) Program of the Department of Anesthesiology, Critical Care and Pain Medicine at Boston Children's Hospital
Background: The gram-negative bacterial pathogen Pseudomonas aeruginosa causes a wide range of infections, mostly in hospitalized and immunocompromised patients, those with burns, surgical wounds, or combat-related wounds, and in people with cystic fibrosis. The increasing antibiotic resistance of P. aeruginosa confers a pressing need for vaccines, yet there are no P. aeruginosa vaccines approved for human use, and recent promising candidates have failed in large clinical trials. Discussion: In this review, we summarize recent clinical trials and pre-clinical studies of P. aeruginosa vaccines and provide a suggested framework for the makeup of a future successful vaccine. Murine models of infection suggest that antibodies, specifically opsonophagocytic killing antibodies (OPK), antitoxin antibodies, and anti-attachment antibodies, combined with T cell immunity, specifically T(H)17 responses, are needed for broad and potent protection against P. aeruginosa infection. A better understanding of the human immune response to P. aeruginosa infections, and to vaccine candidates, will eventually pave the way to a successful vaccine for this wily pathogen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据